The firm's capital structure is heavily reliant on external funding, evidenced by an accumulated deficit of $1.0 billion and a reliance on dilutive financing to maintain its $297.7 million cash position as of 2026Q1.
| Total Current Assets | 396.79M | 205.46M | 157.3M | 129.73M | 219.64M | 222.61M | 158.9M | 86.3M | 128.64M | 70.66M | 39.97M | 55.7M |
| Cash & Short-Term Investments | 381.32M | 187.85M | 148.92M | 123.64M | 213.72M | 207.78M | 154.74M | 83.52M | 122.46M | 69.09M | 37.66M | 55.39M |
| Cash Only | 297.74M | 59.9M | 80.23M | 74.02M | 155.38M | 119.14M | 154.74M | 76.04M | 86.37M | 52.08M | 7.68M | 28.59M |
| Short-Term Investments | 83.58M | 127.95M | 68.69M | 49.63M | 58.34M | 88.64M | 0 | 7.48M | 36.1M | 17.01M | 29.98M | 26.79M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 110K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | 2.95 | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 2.98M | 17.61M | 1.65M | 2.11M | 3M | 8.71M | 1.48M | 1.49M | 1.81M | 613K | 235K | 88K |
| Total Non-Current Assets | 26.1M | 27.08M | 31.36M | 35.2M | 40.61M | 9.77M | 12.27M | 17.17M | 10.96M | 5.54M | 664K | 0 |
| Property, Plant & Equipment | 25.21M | 26.09M | 29.04M | 33.16M | 38.61M | 7.6M | 11.73M | 16.63M | 10.42M | 2.43M | 452K | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | 0.21x | 1.79x | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 183K | 991K | 2.32M | 2.04M | 2.01M | 2.16M | 536K | 536K | 536K | 3.11M | 212K | 0 |
| Total Assets | 422.89M | 232.54M | 188.66M | 164.94M | 260.25M | 232.38M | 171.17M | 103.47M | 139.6M | 76.19M | 40.64M | 55.7M |
| Asset Turnover | 0.00x | - | - | - | 0.03x | 0.06x | - | - | - | - | - | - |
| Asset Growth % | 109.01% | 23.26% | 14.38% | -36.62% | 11.99% | 35.76% | 65.43% | -25.88% | 83.21% | 87.5% | -27.04% | - |
| Total Current Liabilities | 30.28M | 33.47M | 30.26M | 14.52M | 22.51M | 23.6M | 24.48M | 18.28M | 12.48M | 11.27M | 6.87M | 13.92M |
| Accounts Payable | 5.56M | 3.22M | 4.24M | 2.03M | 3.24M | 4.46M | 3.27M | 7.12M | 3.69M | 5.07M | 2.98M | 608K |
| Days Payables Outstanding | 2.56K | 719.29 | 629.94 | 287.36 | - | - | 304.69 | 920.77 | 860.29 | - | 19.45K | - |
| Short-Term Debt | 2.19M | 2.1M | 0 | 0 | 0 | 0 | 0 | 0 | 173K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 8.08M | 10.36M | 0 | 8.23M | 233K | 345K | 0 |
| Other Current Liabilities | 18.15M | 28.14M | 9.37M | 5.95M | 8.38M | 3.12M | 3.83M | 3.63M | 4.91M | 4.17M | 2.38M | 13.06M |
| Current Ratio | 13.10x | 6.14x | 5.20x | 8.94x | 9.76x | 9.43x | 6.49x | 4.72x | 10.31x | 6.27x | 5.82x | 4.00x |
| Quick Ratio | 13.10x | 6.14x | 5.20x | 8.94x | 9.76x | 9.43x | 6.49x | 4.72x | 10.31x | 6.27x | 5.82x | 4.00x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 18.48M | 19.06M | 21.16M | 23.94M | 26.08M | 568K | 14.6M | 5.15M | 1.93M | 124.18M | 71.65M | 61.7M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 859K | 0 | 0 | 0 |
| Capital Lease Obligations | 77.31M | 19.06M | 21.16M | 23.94M | 25.98M | 568K | 2.94M | 5.15M | 859K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 96K | 0 | 1.3M | 0 | 215K | 0 | 71.65M | 61.7M |
| Total Liabilities | 48.76M | 52.53M | 51.42M | 38.46M | 48.59M | 24.17M | 39.08M | 23.42M | 14.41M | 135.45M | 78.52M | 75.62M |
| Total Debt | 20.67M | 21.16M | 24.18M | 26.27M | 28.55M | 2.06M | 5.15M | 7.07M | 1.03M | 0 | 0 | 0 |
| Net Debt | -277.07M | -38.74M | -56.06M | -47.75M | -126.84M | -117.07M | -149.59M | -68.97M | -85.33M | -52.08M | -7.68M | -28.59M |
| Debt / Equity | 0.06x | 0.12x | 0.18x | 0.21x | 0.13x | 0.01x | 0.04x | 0.09x | 0.01x | - | - | - |
| Debt / EBITDA | -0.11x | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.42x | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -3198.45x | - | -365.76x | - | - | - | - | - | - | - | - | - |
| Total Equity | 374.13M | 180.01M | 137.25M | 126.48M | 211.67M | 208.21M | 132.09M | 80.05M | 125.18M | -59.26M | -37.89M | -19.93M |
| Equity Growth % | 122.36% | 31.16% | 8.51% | -40.24% | 1.66% | 57.63% | 65.01% | -36.06% | 311.25% | -56.41% | -90.14% | - |
| Book Value per Share | 3.41 | 2.06 | 3.36 | 6.36 | 24.87 | 29.25 | 38.15 | 29.80 | 56.44 | -27.57 | -29.55 | -15.54 |
| Total Shareholders' Equity | 374.13M | 180.01M | 137.25M | 126.48M | 211.67M | 208.21M | 132.09M | 80.05M | 125.18M | -59.26M | -84.36M | -67.51M |
| Common Stock | 98K | 79K | 40K | 20K | 20K | 7K | 87K | 48K | 35K | 65.01M | 558K | 208K |
| Retained Earnings | -1.01B | -957.77M | -783.45M | -658.75M | -562.74M | -476.76M | -404.57M | -316.28M | -199.06M | -124.26M | -84.94M | -67.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -13K | 52K | 47K | 15K | -68K | -45K | 0 | 1K | -5K | -13K | 23K | -10K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46.47M | 47.59M |
Imminent Capital Dilution Risk
As reported in financial statements, the company's total assets have fluctuated significantly, peaking at $422.9 million in 2026Q1, yet this growth is largely driven by capital raises rather than organic value creation, signaling a precarious trajectory for a pre-revenue entity reliant on external funding.
The volatility in total assets suggests that the company is in a constant state of re-capitalization to offset its persistent operating losses. Investors should monitor whether these asset injections are effectively translating into clinical milestones or merely serving to extend the firm's survival in a high-burn environment.
Based on recent SEC filings, the company's cash position dropped from $297.7 million in 2026Q1 to significantly lower levels in prior periods, highlighting a high-burn profile that necessitates frequent access to capital markets to maintain its clinical development runway for the SGT-003 program.
While the current ratio of 13.10 appears robust on the surface, it is a misleading metric for a pre-revenue biotech firm with no commercial cash inflows. The rapid consumption of cash reserves indicates that the company's liquidity buffer is highly sensitive to clinical trial delays and manufacturing cost overruns.
According to historical balance sheet data, equity has been subject to significant volatility, reflecting the company's reliance on dilutive equity financing to fund its $1.0 billion in accumulated deficit, which underscores the ongoing challenge of preserving shareholder value in a capital-intensive research model.
The persistent growth of the accumulated deficit suggests that the company is effectively trading equity for time. Investors should be wary of the potential for further dilution as the firm approaches critical clinical readouts and requires additional capital to sustain its research pipeline.
As indicated by the company's reported figures, the absence of goodwill and the concentration of assets in cash and PPE suggest a lean, research-focused balance sheet, yet this lack of tangible commercial assets leaves the firm highly vulnerable to any failure in its core gene therapy platform.
The reliance on specialized PPE for viral vector production represents a significant sunk cost that may hold little value if the SGT-003 program fails to meet regulatory standards. This asset structure implies that the company's valuation is almost entirely tied to the success of its clinical pipeline rather than its underlying balance sheet strength.
Quick answers to the most common questions about buying SLDB stock.
As of 2025, Solid Biosciences Inc. (SLDB) had total assets of $232.5M including $205.5M in current assets.
Solid Biosciences Inc. (SLDB) carries total debt of $21.2M, offset by $187.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Solid Biosciences Inc. (SLDB) has total shareholders' equity (book value) of $180.0M ($2.06 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Solid Biosciences Inc. (SLDB) reported a current ratio of 6.14x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.